ArticlePloS one2008
Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review).International journal of molecular medicine · 2023Pooled it
- The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026Review
- Moesin is an αCellular and molecular life sciences : CMLS · 2026Article
- RNA-binding proteins as therapeutic targets in cancer.RNA biology · 2025Review
- Computational investigation of the sequence context of arginine/glycine-rich motifs in the human proteome.BMC genomics · 2025Article
- Deciphering ovarian cancer heterogeneity through spatial transcriptomics, single-cell profiling, and copy number variations.PloS one · 2025Article
- Nucleolin promotes angiogenesis and endothelial metabolism along the oncofetal axis in the human brain vasculature.JCI insight · 2023Article
- RG/RGG repeats in the C. elegans homologs of Nucleolin and GAR1 contribute to sub-nucleolar phase separation.Nature communications · 2022Article
- Article
- Impairment of Nucleolin Activity and Phosphorylation by a Trachylobane Diterpene fromInternational journal of molecular sciences · 2022Article
- Extracellular PKCδ signals to epidermal growth factor receptor for tumor proliferation in liver cancer cells.Cancer science · 2022Article
- Overexpression of Nucleolin and Associated Genes in Prostate Cancer.International journal of molecular sciences · 2022Article
- Cell surface nucleolin is a novel ADAMTS5 receptor mediating endothelial cell apoptosis.Cell death & disease · 2022Article
- Article
- The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options.Cancers · 2021Review
- Identification of Nucleolin as a Novel AEG-1-Interacting Protein in Breast Cancer via Interactome Profiling.Cancers · 2021Article
- Homing Peptides for Cancer Therapy.Advances in experimental medicine and biology · 2021Review
- Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma.Cancer management and research · 2021Article
- Iron Oxide Nanoparticles as Carriers for DOX and Magnetic Hyperthermia after Intratumoral Application into Breast Cancer in Mice: Impact and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2020Article
- PRMT1-mediated methylation of the microprocessor-associated proteins regulates microRNA biogenesis.Nucleic acids research · 2020Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidences suggest that nucleolin expressed on the cell surface is implicated in growth of tumor cells and angiogenesis. Nucleolin is one of the major proteins of the nucleolus, but it is also expressed on the cell surface where is serves as a binding protein for variety of ligands implicated in cell proliferation, differentiation, adhesion, mitogenesis and angiogenesis. METHODOLOGY/PRINCIPAL
findingsBy using a specific antagonist that binds the C-terminal tail of nucleolin, the HB-19 pseudopeptide, here we show that the growth of tumor cells and angiogenesis are suppressed in various in vitro and in vivo experimental models. HB-19 inhibited colony formation in soft agar of tumor cell lines, impaired migration of endothelial cells and formation of capillary-like structures in collagen gel, and reduced blood vessel branching in the chick embryo chorioallantoic membrane. In athymic nude mice, HB-19 treatment markedly suppressed the progression of established human breast tumor cell xenografts in nude mice, and in some cases eliminated measurable tumors while displaying no toxicity to normal tissue. This potent antitumoral effect is attributed to the direct inhibitory action of HB-19 on both tumor and endothelial cells by blocking and down regulating surface nucleolin, but without any apparent effect on nucleolar nucleolin. CONCLUSION/SIGNIFICANCE: Our results illustrate the dual inhibitory action of HB-19 on the tumor development and the neovascularization process, thus validating the cell-surface expressed nucleolin as a strategic target for an effective cancer drug. Consequently, the HB-19 pseudopeptide provides a unique candidate to consider for innovative cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.